By Nascent Biotech Posted November 25, 2019 In HAH 2020 CFP 2pp Leaflet-2 copy2019-11-252019-11-25http://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttp://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.png200px200px 0 HAH 2020 CFP 2pp Leaflet-2 copy Recent PostsNascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting GlioblastomaNascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerNascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive InvestorsNascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody